These 2 Medical Device Stocks Are the “Money Printers” of the Next Decade!
Fellow investors, don’t panic about the recent pullback in medical device stocks! 📉 ISRG and DXCM are down 13% and 12% over the past year, underperforming the market big time. Tariffs, more competition, product recalls—bad news keeps piling up. But smart investors know: short-term market sentiment always hides the true value of great companies. Look past the current fog, and these two firms have rock-solid fundamentals, even more attractive than ever. If you’re willing to think long-term—10 years out—these stocks could be the steady money printers in your portfolio.
Over the past year, shares of medical device leaders Intuitive Surgical (ISRG) and DexCom (DXCM) have fallen 13% and 12% respectively, significantly underperforming the broader market. Tariff impacts, intensifying competition, product recalls… bad news seems to keep coming. But savvy investors understand that short-term market sentiment often masks the true value of high-quality enterprises. Beyond the current haze, the fundamentals of these two companies remain solid—even more attractive than ever before.
If you’re willing to look ahead to the next decade, these two stocks are highly likely to become a steady stream of “money printers” in your investment portfolio.
$Intuitive Surgical(ISRG)$: The Absolute King of Surgical Robots—Short-Term Headwinds Are Nothing to Fear
As the hegemon in the field of robot-assisted surgery, Intuitive Surgical did face troubles in 2025. On one hand, tariff policies eroded profits; on the other hand, Medtronic’s Hugo system received U.S. approval for urological surgeries, triggering market concerns about market share loss.
However, these challenges will not shake the company’s long-term foundation. First, global population aging is an irreversible mega-trend. By 2034, the number of people aged 65 and above in the U.S. will exceed those under 18 for the first time—meaning demand for minimally invasive surgery will grow exponentially, and Intuitive Surgical’s da Vinci system is the biggest beneficiary of this trend.
Second, the company has a wide and deep moat. The da Vinci system is expensive, and once a hospital purchases it and trains doctors to use it, the switching costs are extremely high. More importantly, Intuitive Surgical never stops innovating—iterations of its next-generation systems and continuous expansion of indications keep the company one step ahead of its competitors. Even with the entry of rivals like Medtronic, they can only grab a share of the incremental market, not shake Intuitive Surgical’s existing market share.
As for the tariff issue, with the company’s global installed base of over 11,106 units, its pricing power is strong enough to offset cost impacts through small price increases. As surgical volumes continue to rise, the growth engine for revenue and profits is far from stalling.
$DexCom(DXCM)$: The Leader in Continuous Glucose Monitoring—Huge Room for Penetration Growth
DexCom’s story is equally compelling. Last year, the company recalled some CGM receivers due to malfunctions, but this only affected a tiny number of patients and had minimal impact on the overall business. What’s truly worth watching is the huge growth opportunity behind the company. In the CGM market, DexCom and Abbott are regarded as the two giants, but penetration remains very low. In the U.S. alone, more than 9 million insured diabetes patients have not yet used CGM, while DexCom’s global total user base is only about 3.5 million—the gap between these two numbers is an untapped goldmine.
Even more exciting is that DexCom is expanding into non-diabetic populations. Its over-the-counter product Stelo, approved in 2024, has attracted more than 500,000 users since its launch. Over 40% of U.S. adults are in pre-diabetes—a nearly unlimited market. In the future, with product iterations, international market expansion, and expanded indications, DexCom’s growth ceiling will continue to rise.
Conclusion
Short-term volatility is a product of Mr. Market’s mood, not a true reflection of a company’s value. The current slump of Intuitive Surgical and DexCom has precisely provided a rare buying window for long-term investors. Over the next decade, multiple drivers—aging demand, technological innovation, and rising market penetration—will push these two medical device leaders to continuously generate cash flow. Don’t be fooled by the recent drop; they are the real “money printers” worth holding for 10 years.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
